Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | RAB9A | P51151 | 5/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13856767 | 0.90 | MAOB (0.67) | KMT2ASMN1; SMN2RAB9AL3MBTL1NPC1 | |
| SCHEMBL18012070 | 0.85 | NPC1 (0.85) | KMT2ASMN1; SMN2RAB9AL3MBTL1NPC1 | |
| SCHEMBL16541098 | 0.83 | RAB9A (1.00) | KMT2ASMN1; SMN2RAB9AL3MBTL1NPC1 | |
| SCHEMBL6345667 | 0.82 | KMT2A (0.61) | KMT2ASMN1; SMN2RAB9AL3MBTL1NPC1 | |
| SCHEMBL289081 | 0.82 | NPC1 (1.00) | KMT2ASMN1; SMN2RAB9AL3MBTL1NPC1 | |
| SCHEMBL9594944 | 0.81 | NPC1 (0.60) | KMT2ASMN1; SMN2RAB9AL3MBTL1NPC1 | |
| SCHEMBL12325869 | 0.79 | NPC1 (0.74) | KMT2ASMN1; SMN2RAB9AL3MBTL1NPC1 | |
| SCHEMBL28171359 | 0.79 | RAB9A (0.55) | KMT2ASMN1; SMN2RAB9AL3MBTL1NPC1 | |
| SCHEMBL8761733 | 0.79 | MAOB (0.61) | KMT2ASMN1; SMN2RAB9AL3MBTL1NPC1 | |
| SCHEMBL299172 | 0.79 | PTGS2 (0.71) | KMT2ASMN1; SMN2RAB9AL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2636670-B1 | Process for preparing benzofurans | CAMBREX KARLSKOGA AB (SE) | 2016-06-01 | — | — | EP | disclosed |
| EP-2417099-B1 | NEW PROCESS FOR PREPARING HYDROXYLAMINES AND MEDICAMENTS | CAMBREX KARLSKOGA AB (SE) | 2015-12-23 | — | — | EP | disclosed |
| CN-102459154-B | For the preparation of the novel method of azanol class and medicine | CAMBREX KARLSKOGA AB (SE) | 2015-12-02 | — | — | CN | disclosed |
| EP-2388256-B1 | Process for preparing benzofurans | CAMBREX KARLSKOGA AB (SE) | 2015-11-25 | — | — | EP | disclosed |
| CN-102171200-B | For the preparation of the method for diones and medicine | CAMBREX KARLSKOGA AB (SE) | 2015-09-30 | — | — | CN | disclosed |
| US-20140206761-A1 | PROCESS FOR PREPARING HYDROXYLAMINES AND MEDICAMENTS | CAMBREX KARLSKOGA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-8779201-B2 | Process for preparing benzofurans | CAMBREX KARLSKOGA AB (SE) | 2014-07-15 | — | — | US | disclosed |
| US-20130338398-A1 | Process for Preparing Benzofurans | CAMBREX KARLSKOGA AB (SE) | 2013-12-19 | — | — | US | disclosed |
| CN-103342633-A | Process for preparing benzofurans | CAMBREX KARLSKOGA AB | 2013-10-09 | — | — | CN | disclosed |
| EP-2636670-A1 | Process for preparing benzofurans | Cambrex Karlskoga AB (SE) | 2013-09-11 | — | — | EP | disclosed |
| EP-2356100-A1 | NEW PROCESS FOR PREPARING DIKETONES AND MEDICAMENTS | Cambrex Karlskoga AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-20100292319-A1 | PROCESS FOR PREPARING BENZOFURANS | CAMBREX KARLSKOGA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| WO-2010116140-A1 | NEW PROCESS FOR PREPARING HYDROXYLAMINES AND MEDICAMENTS | CAMBREX KARLSKOGA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| CN-101861308-A | Process for the preparation of benzofuran compounds | CAMBREX KARLSKOGA AB | 2010-10-13 | — | — | CN | disclosed |
| EP-2200993-A2 | PROCESS FOR PREPARING BENZOFURANS | Cambrex Karlskoga AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010038029-A1 | NEW PROCESS FOR PREPARING DIKETONES AND MEDICAMENTS | CAMBREX KARLSKOGA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009044143-A2 | PROCESS FOR PREPARING BENZOFURANS | CAMBREX KARLSKOGA AB (SE) | 2009-04-09 | — | — | WO | disclosed |
| US-5266711-A | Process for the preparation of 3-benzoyl benzofuran derivatives | SANOFI (FR) | 1993-11-30 | — | — | US | disclosed |
| US-4001426-A | HAVING CORONARY VASODILATOR ACTIVITY | SMITHKLINE CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3975537-A | SUBSTITUTED BENZOFURANS | SMITH KLINE (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338398-A1 | Process for Preparing Benzofurans | CYP2F1, CYP4X1, CYP3A4 | KMT2A 3482/4885SMN1; SMN2 2569/4885RAB9A 740/4885 |
| US-20140206761-A1 | PROCESS FOR PREPARING HYDROXYLAMINES AND MEDICAMENTS | CYP3A4, CYP1A2, CYP2D6 | KMT2A 1668/4885SMN1; SMN2 4537/4885RAB9A 1617/4885 |
| US-20100292319-A1 | PROCESS FOR PREPARING BENZOFURANS | CYP2F1, CYP3A4, CYP4F3 | KMT2A 3717/4885SMN1; SMN2 2428/4885RAB9A 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.